"It wouldn't surprise me that improving people's health this way actually slows down the ageing process," Prof Krumholz was quoted on Friday as telling the European Society of Cardiology Conference 2024, where the studies were presented
Rekha Kumar, endocrinologist at Weill Cornell Medicine
Conclusions In this real-world cohort of adults with overweight or obesity without diabetes, liraglutide, semaglutide, and tirzepatide were all associated with clinically meaningful weight loss and favorable metabolic effects over 36 weeks of treatment
This new integration complements our insurance-sponsored pharmacy programs, where we continue to see rising approval rates for branded GLP-1 therapies like Zepbound
Nine months later a 2mg dose of Ozempic became available
These decisions require individualized clinical discussion, not a one-size-fits-all protocol